Pre-clinical and clinical data on pancreatic cancer has shown that LOXL2 is correlated with the invasiveness of pancreatic cancer and has the potential to be used as an independent prognostic marker and therapeutic target (59). Here, LOXL2 is linked to familial pancreatic carcinoma.